Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

of 44 /44
Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech. BIO International Convention June 27-30, 2011 Washington D.C.

Embed Size (px)

Transcript of Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech
University of Cologne Institute of Biochemistry
n Page 5: Düsseldorf Marketing & Tourismus
n Page 10-11: ATTO-TEC GmbH
n Page 12-13: Bayer Innovation
n Page 14-15: BioMedizinZentrum Dortmund
n Page 17: BIO.NRW; Max Planck Institute for
Molecular Biomedicine, Münster
n Page 22-23: City of Düsseldorf – Office of Economic Development,
Düsseldorf Marketing & Tourismus GmbH
n Page 27: Cologne Bonn Business
n Page 29: Lead Discovery Center GmbH
n Page 30-31: Leibniz-Institut für Analytische Wissenschaften - ISAS
n Page 33: Miltenyi Biotec GmbH
n Page 35: NRW International
n Page 37: PAION AG
n Page 38-39: Syntab, Darren Baker -
CEVEC Pharmaceuticals GmbH ............................................ 18
chemagen Biopolymer-Technologie AG .............................. 20
CLIB2021 Cluster Industrial Biotechnology ........................... 24
Cologne Bonn Business ........................................................ 26
Leibniz-Institut für Analytische Wissenschaften - ISAS ...... 30
Miltenyi Biotec GmbH ........................................................... 32
Organisation / Sponsors .......................................................41
North Rhine-Westphalia – We create opportunities!
North Rhine-Westphalia is Germany’s number one centre of chemical and pharmaceutical industry – with an increasing focus on sustainable economic development and the needs of the people. This includes an effective and efficient health sector and cutting-edge environment industries, plus innovative biotechnology which, as an interface technology with a vast potential for generating applications, is a mainstay of numerous industries in our state.
In North Rhine-Westphalia, some 70 university and non- university institutions and other scientific facilities are doing research in biotechnology and the life sciences.
In 2009 around 300 life science-related companies with 70 dedicated biotech companies (OECD definition) were located in North Rhine-Westphalia. According to the “OECD Biotechnological Statistics report”, North Rhine- Westphalia is Europe’s most innovative biotechnology region: It generates more biotech PCT patent applications than any other European region. Their economic impact is highlighted by the fact that more than 40 per cent of the overall German biotech turnover is generated in our state.
of the German State
We are putting an extra emphasis on creating the best possible framework for research and development, on sustainability, on better co-operation between academia and industry and on internationalization. We want to tap the full potential.
An example for this is the hosting of BioEurope in Düsseldorf, the North Rhine-Westphalia capital, in 2011. I’d like to invite you to visit this great event from 31st of October to 2nd of November 2011.
We look forward to welcome you at the BIO.NRW booth to meet innovative companies from North Rhine-Westphalia and contact partners for co-operation.
Svenja Schulze Minister for Innovation, Science and Research of the State of North Rhine-Westphalia
Dear visitors and exhibitors,
The State of North Rhine-Westphalia (NRW) along with 12 companies and institutions is pleased to attend the BIO International Convention and to present the diversity and innovative potential of the biotech scene in NRW.
The largest German federal state North Rhine-Westphalia is situated at Europe’s geographic and economic center. In total, the state is home to more than 300 life science companies, among them 71 core biotechnology firms that together account for 42 % of German biotech turnover (according to the OECD definition). With 50 universities and research institutions conducting life science research, NRW also enjoys the highest concentration of academic institutions within Europe, as well as being Europe’s leading region when it comes to patenting biotech inventions.
One notable strength of NRW’s biotech industry is industrial (‘white’) biotechnology, which benefits from the state’s strong chemical industry. This sector is networked by the Cluster of Industrial Biotechnology, named CLIB2021.
The NRW events organized jointly by BIO.NRW and NRW. International at the German pavilion once again offer
Almut Schmitz
CEO NRW.International
numerous opportunities to make contact with companies from Germany’s largest federal state. This brochure provides an initial overview of the companies’ products and services and invites you to visit our stand No. 2224 in Hall A. We wish you every success at the BIO International Convention 2011.
Dr. Bernward Garthoff Almut Schmitz Chair of Cluster Biotechnology CEO NRW.International North Rhine-Westphalia
Cologne Bonn Business
Lead Discovery Center
7.00 p.m. - 11.00 p.m. NRW Biotech Networking Reception
Venue: Hudson Restaurant and Lounge 2030 M Street NW, Washington D.C.
Meet your North Rhine-Westphalian and international business partners and decision makers. Enjoy a fabulous night with food, drinks and live music.
RSVP: [email protected]
A shuttle bus will be provided directly from the BIO International Convention to the venue.
Meeting Point: 6:30 p.m. at the BIO.NRW booth, 2224
Wednesday, June 29th
Novel opportunities and biotech solutions in the future health care market
Venue: Renaissance Washington, D.C. Downtown Hotel 999 Ninth Street NW, Washington, District of Columbia 20001
08:30 a.m. Breakfast
09:00 a.m. Welcome Address Richard Gallagher, Chief Editor “Spotlight on Biotechnology”, San Francisco, USA
09:10 a.m. Health Care Market of the Future: Perspectives of biotech solutions Bill Huyett, Director McKinsey & Co., Boston, USA
09:40 a.m. Plant Made Pharmaceuticals: A vaccine for follicular lymphoma John Edward Butler, Bayer Innovation GmbH, Düsseldorf, Germany, Dava Oncology LP, Dallas, USA
10:00 a.m. Novel (stem-) cell based diagnostics and therapeutics towards bedside applications Kai Pinkernell, Head of Clinical Development, Miltenyi Biotec, Bergisch Gladbach, Germany
10:20 a.m. Panel Discussion
Cologne Bonn Business
Lead Discovery Center
Fluorescence - What else?
Since the start up in 1999 ATTO-TEC is committed to being a first class provider of novel fluorescent labels that advance bioanalytical and biomedical research all over the world. More than 40 years of academic know-how were condensed into the company in order to develop innovative fluorescent solutions for the life science market. Science has always been a priority at ATTO-TEC. Our current staff brings together long-time expertise in dye chemistry and physics. We combine highest quality standards for all our products with an individualized customer support.
n Joerg Reichwein (CEO), [email protected]
n Jutta Arden-Jacob (R&D Manager), [email protected]
n Alexander Zilles (R&D Manager), [email protected]
Reseachers prefer ATTO-Labels for their high purity and excellent performance. In many applications our dyes are not merely an alternative, they are the better choice.
We are proud to present a new range of innovative fluorescent labels which show excitation and emission spectra that match all commonly used light sources and filters. It is a pleasure to introduce you to ATTO-TEC – the company that creates success with fluorescent dyes.
What we are looking for at the BIO International Convention
ATTO-TEC is looking for collaborations in the field of developing new fluorescent dyes and new products labeled with ATTO-Dyes which can be used for diagnostic and analytical detections.
About Bayer Innovation GmbH and Icon Genetics
Bayer Innovation GmbH (BIG), a wholly owned subsidiary of Bayer AG, evaluates and develops new fields of business for the Bayer Group are related to Bayer’s core competencies of health care, nutrition and innovative materials and complement its current key areas of innovation and business.
Icon Genetics is a wholly owned subsidiary of Bayer Innovation GmbH; it was established in 1999 and acquired by Bayer in 2006. The company develops processes for the biotechnological production of proteins and other high- value products in plants.
Bayer: Science For A Better Life Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. The company’s products and services are designed to benefit people and improve their quality of life. At the same time Bayer creates value through innovation, growth and improved earning power. The Group is committed to the principles of sustainable development and acknowledges and accepts its role as a socially and ethically responsible “corporate citizen”. Economy, ecology and social
Bayer Innovation
n Dr. John Butler (Global Project Leader), [email protected]
responsibility are corporate policy objectives of equal rank. In fiscal 2007, Bayer employed 106,200 people and had sales of EUR 32.4 billion. Capital expenditures amounted to EUR 1.9 billion, the R&D budget to EUR 2.6 billion. More information is available on the Internet at
What we are looking for at the BIO International Convention
Codevelopment partner autologous cancer vaccine
The biotech industry calls for coordinated business solutions. Product development within this area requires special laboratories with customized technical equipment. It is precisely here that the BMZ maintains cutting-edge infrastructures.
Dortmund – Gateway to the Future The BMZ is located in the TechnologieParkDortmund in close proximity to the Technische Universität Dortmund,
Address/P.O. Box
Postal Code/City
n Andre van Hall (Head of BMZ), [email protected]
the Max Planck Institute of Molecular Physiology, the Leibniz-Institut für Analytische Wissenschaften (ISAS).
The local infrastructure provides an effective platform for technology transfer and the potential for close cooperation with the academic and business community.
The central location of Dortmund at the heart of the region’s health care industry also opens up excellent opportunities for high-end networking. Alongside its state-of-the-art research facilities, the site offers an extensive range of industrial properties, providing ample scope for the future growth of ambitious companies.
What we are looking for at the BIO International Convention
n Location marketing for the biotech region Dortmund n Attract new partners for the region Dortmund n Intensify collaboration with other biotech locations and networks n Supporting companies which are located within the BMZ
BIO.NRW - Busyness for Biotech.
North Rhine-Westphalia’s biotechnology cluster BIO.NRW is a central catalyst for the sustainable development of the state’s biotech sector. It activates cooperation between business, research, investors and policy-makers. The cluster also promotes the strengths and achievements of biotechnology in the state: industrial biotechnology and pharmaceutical biotechnology.
BIO.NRW is part of an initiative by North Rhine-Westphalia’s (NRW) state government, which aims at making NRW the number one state for innovation. It has therefore established 16 technology clusters to systematically improve NRW’s strengths and talents in established industries and up-and-coming fields like biotechnology.
Goal of the “Excellence NRW” cluster strategy is to create a favourable climate for innovation, as that is the best way to sustain the competitive edge and stimulate growth and employment in the companies that call the state their home.
Services n Technology Transfer n Support of Biotech Companies, esp. SME n Support of Biotech Start-ups, Coaching & Financing n National and International Fairs, Exhibitions, and Conferences
Address/P.O. Box
Postal Code/City
n Annette Angenendt (PR & Marketing), [email protected]
n Dr. Bernward Garthoff (Chair of Cluster Biotechnology North
Rhine Westphalia), [email protected]
n Dr. Nils Schrader (Science Officer), [email protected]
n Analysis of biotechnology in North Rhine-Westphalia for location data
n Marketing & PR for the biotech state of North Rhine- Westphalia
n Promotion of young academics
What we are looking for at the BIO International Convention
n To showcase North-Rhine Westphalia’s strenghts in the Biotech Business
n Enabling NRW’s Biotech Companies and Institutions to pursue their business
n To foster targeted B2B Partnering n To seek and intensify international cooperation n To discuss the latest innovations in NRW
Human Cells for Human Pharmaceuticals
CEVEC’s amniocyte derived protein expression technologies CAP and CAP-T are designed for stable and transient protein production. They achieve highest protein yields with authentic human glycosylation patterns. The versatile cells exhibit exceptional yields for antibodies and complex proteins and are also an excellent tool for vaccine/virus production.
The stable producer CAP cell line and the new transient CAP-T cell line meet all regulatory guidelines, are adopted to serum-free growth conditions and can be very efficiently transfected with commercially available transfection reagents. They are optimized to grow in a variety of flask/ wave formats up to large-scale processing in bioreactors. Especially in the US the company is enjoying a broad and growing interest of pharma and biotech companies in employing the CAP and the CAP-T technology as the one and only cell expression system to be used from early discovery expression tasks (CAP-T) up to large-scale production purposes (CAP).
Gottfried-Hagen-Str. 62
51105 Cologne
+49-(0)221-460208 00
+49-(0)221-460208 01
platform for transient / stable cell line development for the production
of complex / difficult to express proteins and for the production of
vaccines and viruses. Custom cell line and process development service.
n Dr. Rainer Lichtenberger (CEO),
[email protected]
[email protected]
[email protected]
North America), [email protected]
[email protected]
What we are looking for at the BIO International Convention
CEVEC intends to attract additional potential customers by presenting the company and the benefits of CAP- Technology during partnering sessions. Based on recent
success regarding the use of CAP as a vaccine and virus production platform, the company also prepares for another venture round with potential US participation.
It‘s chemagic!
chemagen is a key player in the field of manual and automated nucleic acid isolation. chemagen’s kits and automation platforms facilitate DNA/RNA isolation from all clinical sample materials, such as blood, serum, plasma, urine, swabs, saliva, cells, etc.
chemagen’s high performance instrument is the chemagic Magnetic Separation Module I (chemagic MSM I) which can process 1 – 96 samples in one hour. It enables high throughput applications as well as large volume applications up to 10 ml. Combining the chemagic MSM I with a liquid handling unit enables a fully automated workflow from primary samples to e.g. PCR setup.
The chemagic Prepito, chemagen’s benchtop solution, facilitates the nucleic acid isolation of 1 - 12 samples from up to 1000 µl sample volume. Its integrated dispensing system reduces hands on time. The chemagic Prepito includes barcode reading to provide comfort and to support highest quality assurance demands.
chemagen Biopolymer-Technologie AG
manual), large scale protein purification
chemagic Separation Technology, M-PVA Magnetic Beads
chemagic Magnetic Separation Module I, chemagic Prepito,
chemagic Kits for nucleic acid isolation
Address/P.O. Box
Postal Code/City
Contact Person at the BIO International Convention
n Dr. Lothar à Brassard (CEO), [email protected]
Both automated systems use chemagen’s proprietary separation technology based on polyvinyl alcohol (PVA) Magnetic Beads. These Magnetic Beads are also available with different functionalities adapted to the customer’s needs.
The PVA Magnetic Beads are also applicable for high throughput protein purification and binds up to 1 g of the target protein. The large scale protein purification system facilitates applications such as Bio-Production and Bio-Separation.
Outstanding robustness, minimal hands-on time, fast and accurate performance – It´s chemagic!
What we are looking for at the BIO International Convention
Cooperation partners in the field of nucleic acid based diagnostics, and magnetic bead based applications.
Supports life science companies situated in the Düsseldorf region, promotes the life science location Düsseldorf internationally and supports companies from North America and Asia in entering the European markets.
Burgplatz 1
40215 Düsseldorf
+49-(0)211-899 7688
+49-(0)211-893 7688
- Assists foreign companies in setting up their business in Düsseldorf
- Advises companies on permits and authorizations
- Procures industrial property, buildings, offices and laboratories
- Organizes financial assistance for young companies
Economic Development City of Düsseldorf
City of Düsseldorf – Office of Economic Development
Address/P.O. Box
Postal Code/City
[email protected]
The Office of Economic Development co-ordinates LifeScienceNet Düsseldorf, a powerful network of life science companies, universities, research institutions, public administration and biotech parks. As a focal point for life sciences, City of Düsseldorf is member of the BioRiver network, one of Germany’s TOP 4 biotech clusters.
What we are looking for at the BIO International Convention We are looking for companies that are thinking about expanding their business to Germany.
The Cluster CLIB2021 wants to establish industrial biotechnology within the chemical industry, small and mid-sized enterprises (SMEs) and in academia. It actively networks the chemical industry, biotechnology start- ups, SMEs and science institutes, customer industries and investors. CLIB2021 initiates future-oriented R&D
Address/P.O. Box
Postal Code/City
CLIB2021 Cluster Industrial Biotechnology
n Dr. Manfred Kircher (Chairman), [email protected]
projects in industrial biotechnology, strengthening the competitiveness of companies and academic institutes.
The organization supports start-up and project financing and provides expert advice. CLIB2021 has 84 members in Germany, Europe, North-America and Russia.
What we are looking for at the BIO International Convention
Industries, science institutes, governmental organizations and investors willing to partner in the field of industrial biotechnology.
COLOGNE BONN BUSINESS The location marketing agency markets the Cologne Bonn Metropolitan Area
With almost 3.5 million inhabitants, the region is not only one of the most economically strong metropolitan areas in Germany, but also an attractive investment place for domestic and international investors.
To increase the awareness of this business region in this investor-friendly environment, CBB highlights the following powerful industries: Automotive/Engineering, Chemistry, Finance/Insurance, Trade, Logistics, and Media & IT/Telecommunication. In addition, another major advantage of location is the region’s high skilled employees and executive managers in a demographic environment that does not threat at all. CBB is a union between the following local players: eight area municipalities, the saving banks, and the business initiative society of this business region.
Members of the company Standortmarketing Region Köln/Bonn GmbH, which was founded in 2003, are with 40% the business initiative society (Wirtschaftsinitiative Region Köln/Bonn e.V.), with 40% the society of the area municipalities (Verein Region Köln/Bonn e.V.), and with 20% the saving banks (Region Köln/Bonn Sparkassen
Address/P.O. Box
Postal Code/City
Cologne Bonn Business
n Dr. Sylvia Knecht (CEO), [email protected]
n Carsten Weis (Project Manager & Public Relations ),
[email protected]
GbR). CEO of the division COLOGNE BONN BUSINESS of the company Standortmarketing Region Köln/Bonn GmbH is Dr. Sylvia Knecht.
What we are looking for at the BIO International Convention
The Cologne Bonn Metropolitan Area is characterized by an exciting mix of generations; from young, skilled workers, to qualified senior managers. Universities enjoy international reputation. This guarantees a high concentration of educational facilities and a high share of employees with a university education. Numerous patent applications are the indicator of intensive research being conducted. In the Cologne Bonn Metropolitan Area, the buying power per capita is above the national average. The right place for investments.
Paving the way for innovative medicines
Founded in 2008, the recently announced research alliance with Merck KGaA and its first licensing deal with Bayer Schering Healthcare demonstrate that the Lead Discovery Center (LDC) efficiently acts as a translational link between excellent basic research and industry. Active in the field of pharmaceutical research, the LDC transforms promising early-stage projects into pharmaceutical leads being a prime source for external innovation. The LDC is committed to highest industrial quality standards for its Lead products. All leads offered for out-licensing come with proof-of-concept in animal models, solid IP protection and professional in- depth data packages, enabling a smooth transition into an industry partner’s lead optimization and drug development pipeline. Focusing on small molecules, the LDC conducts lead generation projects originating from academic groups as well as industry and sustains a preferred partnership with the Max Planck Society. Projects are developed in close collaboration with the project initiator who is generally one of the key opinion leaders in the respective field. The LDC offers core expertise in Cellular Biology, Assay Development
Address/P.O. Box
Postal Code/City
Chemistry, Drug Discovery
Lead Discovery Center GmbH
& Screening, Pharmacology and Medicinal Chemistry. LDC has no indications limitation as projects benefit from the pathobiology know-how of its wide network into academia and clinic. The LDC team consist of industry-trained experts with solid experience in project management and drug
Contact Person at the BIO International Convention
n Thomas Hegendoerfer (Head of Business Development),
[email protected]
n Dr. Bert Klebl (Managing Director), [email protected]
discovery. Co-managing director Dr. Peter Nussbaumer spent more than 25 years with Novartis, co-managing director Dr. Bert Klebl has previously worked for Hoechst and Axxima among others.
What we are looking for at the BIO International Convention
n Licensing partners for novel Lead projects: • highly selective CDK7 inhibitors (oncology,
inflammation) • Axl kinase inhibitors (metastatic breast cancer) n Pharma partners interested in early partnering and risk
sharing models to access scientific excellence in drug discovery
ISAS - Leading in Bioanalytics and Spectroscopy skills
ISAS is an independent physical and chemical analysis research institute, specialising in the fields of bioanalytics as well as material- and interface spectroscopy. The institute generates solutions for analytical problems, and to this end develops new or improved measuring principles and procedures, analytical techniques, methods and equipment. Since its foundation in 1952, the work of ISAS has been directed mainly towards user orientated basic research in the field of analytical chemistry.
Address/P.O. Box
Postal Code/City
Ruhr-Universität Bochum
n Prof. Dr. Albert Sickmann (Director, Research area Bioanalytics),
[email protected]
The institute has gathered particular expertise in developing new methods and improving existing ones. To solve complex analytical problems various methods have been combined, according to the particular needs (the so-called multi- method concept). A few years ago, new expertise in the life sciences has extended the portfolio of the institute. Now ISAS combines skills in at least two state-of-the-art branches of modern sciences.
The main focus in the Bioanalytics department is the development of methods and procedures for fast and specific detection of proteins and their modifications in complex biological samples (e.g. cells, tissues and liquors). The scientists mainly focus on label free quantitative analytics of complex peptide or protein mixtures for the needs of systems biology.
What we are looking for at the BIO International Convention
We are looking especially for new cooperation partners for R&D projects, academic partners as well as partners from industry.
Partners, taking you from basic research to clinical applications
Miltenyi Biotec, founded in 1989, is a premier provider of advanced products and services in the fields of stem cells, immune and cellular therapies as well as tissue regeneration. As a multinational corporation with more than 1100 employees in 18 countries worldwide, we develop, manufacture and commercialize state-of the-art technologies and products for research and clinical applications. Our product and service offerings cover all areas of cell-based research and clinical development, from sample preparation, cell separation, cell culture, flow cytometric and molecular analysis, including gene expression profiling and DNA analysis, to clinical therapeutic applications and contract GMP manufacturing.
Friedrich-Ebert-Str. 68
immunology, contract manufacturing, customisation and
development services
- Automated sample preparation for a) generation of single cell
suspension, b) rare cell analysis, c) protein analysis and
d) nucleic acid analysis
MACSQuant® Analyzer, MACS® Cell Culture Media & Reagents,
cryoMACS® Freezing bags, CliniMACS®plus System,
CliniMACS® Prodigy System
n Dr. Oliver Bartelsen (Global Head Business Development),
[email protected]
[email protected]
[email protected]
Our research tools, analytical and preparative instruments, clinical-grade reagents and medical devices provide integrated translational solutions that meet the high demands and expectations that Miltenyi Biotec customers have come to expect from a leading biotechnology tool provider
What we are looking for at the BIO International Convention
n Collaboration partners in the areas of stem cells, immune and cellular therapies, tissue regeneration, immunology
n Innovative technologies and reagents for sample preparation, cell separation, cell analysis
n Customers for Genomic Services and Contract Manufacturing Services
NRW.International – Export-Promotion for North Rhine-Westphalia Your partner for industry in the development of growth markets
NRW.International coordinates the promotion of foreign trade in North Rhine-Westphalia. In particular, it supports small and medium-sized enterprises in the development of important growth markets worldwide. It is sponsored by the chambers of commerce and industry in North Rhine-Westphalia, the state’s chambers of crafts and NRW.BANK. The projects are subsidized by the NRW Ministry for Economic Affairs, Energy, Building, Housing and Transport.
The primary objective is to gear the instruments and activities of foreign trade promotion to the requirements of industry. In close coordination with its partners in chambers of commerce and industry, chambers of crafts, economic development agencies, associations, clusters and state initiatives, NRW.International provides a variety of measures tailored to the companies’ needs:
Participation in trade fairs abroad – Companies can present their products and services to a broad audience of trade professionals as part of joint company stands, information service centers or small groups.
Voelklingerstr. 4
40219 Düsseldorf
+49-(0)211-71067 112
+49-(0)211-71067 120
Address/P.O. Box
Postal Code/City
n Bety Chu (Head of International Trade Fairs),
[email protected]
Delegation and entrepreneur trips – Together with its partners, NRW.International organizes and coordinates trips for delegations and entrepreneurs. In keeping with the development and growth potential in the target markets concerned, these activities are accompanied politically by the state government.
Other services – Industry information and cooperation events within the framework of trade fairs or delegation trips round off the services of NRW.International.
Numerous consulting sessions and information events offered by the partners provide companies with additional assistance in establishing and expanding their foreign business. In this way the services are tailored optimally to the needs of the companies and guarantee the efficient and business-friendly promotion of foreign trade.
The PAION Principle
PAION AG is a biopharmaceutical company focusing on the clinical development of drug candidates for diseases or interventions for which there is a substantial unmet medical need.
After proof of concept in humans – the greatest value creating step prior to market approval – the strategy is to out-license or co-develop the drug candidates with pharma partners.
PAION further profits from the receipt of payments for reaching clinical and commercial milestones and receiving royalties after market approval of the drugs. Further upside can be generated from co-commercialisation activities.
With this business model revenues can be generated at an early stage, decreasing development costs and risks.
With currently two development programmes in Phase II , one programme has completed Phase II and two programmes in Phase I, PAION is excellently positioned.
Address/P.O. Box
Postal Code/City
H. Lundbeck A/S, Ono Pharmaceutical Co., Ltd., Acorda
Therapeutics, Inc., Bayer Schering Pharma AG
Remimazolam, Desmoteplase, M6G, Solulin, GGF2
[email protected]
[email protected]
What we are looking for at the BIO International Convention
PAION intends to expand its portfolio of drug candidates and strives to cooperate with experienced partners, particularly during the later stages of clinical development,
regulatory procedures and commercialisation. Due to the recent development progress with Solulin PAION is seeking Partners to develop Solulin in Haemophilia and/or Radiation Injury. For Remimazolam and M6G availability of regional rights is subject to ongoing partnering discussions. PAION is interested in late stage to approved projects ideally in the anaesthesiology or critical care environment.
Syntab Therapeutics is doing research and development of innovative pharmaceuticals. The company owns a proprietary technology platform for the development and production of synthetic antibodies. In early 2011, Syntab
Address/P.O. Box
Postal Code/City
are very welcome. Syntab Therapeutics has already established a
number of contacts to academic and business partners in order to
ensure efficiency in clinical development and short time-to-market.
Syntab Therapeutics’ lead synthetic antibody candidate, SAB-Y1,
is applied in cancer therapy. It is yet in preclinical development. Its
molecular target is the epidermal growth factor receptor (EGFR).
Syntab Therapeutics
n Ute Steinbusch (Scientific Coordinator),
[email protected]
Therapeutics received a grant from the German ministry of education and research in order to validate the synthetic antibody concept within the upcoming 3 years.
The technology platform enables the company to synthesize highly effective drugs against cancer and other
types of diseases. These drugs show the positive effects of monoclonal antibodies (high specificity for the target molecule, activation of the immune system), but they are much smaller and simpler in manufacturing.
What we are looking for at the BIO International Convention
Syntab Therapeutics is focussed on preclinical development of its drug candidates. We are interested in finding pharma partners that can ensure the effective further clinical development and marketing.
Münster Q
Q Dortmund
Q Bielefeld
NRW International GmbH Völklinger Str. 4, 40219 Düsseldorf Phone: +49-(0)211-71 06 71 10 Fax: +49-(0)211-71 06 71 20 [email protected]
sponsored by
Ministry of Economic Affairs, Energy, Building, Housing and Transport of the State of North Rhine-Westphalia Haroldstr. 4, 40213 Düsseldorf Phone: +49-(0)211-83 70 2 Fax: +49-(0)211-83 72 20 0 [email protected]
Ministry of Innovation, Science and Research of the State of North Rhine-Westphalia Völklinger Str. 49, 40221 Düsseldorf Phone: +49-(0)211-89 60 4 Fax: +49-(0)211-89 64 55 5 [email protected]
in cooperation with
BIO.NRW Merowingerplatz 1, 40225 Düsseldorf Phone: +49-(0)211-38 54 69 92 00 Fax: +49-(0)211-38 54 69 92 20 [email protected]
organised by
Organisation / Sponsors